ArticleJHLT open2026
Apixaban versus warfarin for anticoagulation after left ventricular assist device implantation: A multicenter real-world analysis.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation is standard in patients with left ventricular assist devices (LVADs), but the optimal regimen remains uncertain. While warfarin has historically been utilized, the use of direct oral anticoagulants is increasing. Using the TriNetX Collaborative Research Network, we identified adult HeartMate 3 (HM3) LVAD recipients treated with apixaban (n = 174) or warfarin (n = 1782). Propensity-score matching balanced demographics, comorbidities, and laboratory values, yielding 171 patients per cohort. The mean age was 53.3 ± 16.9 years in the apixaban group and 54.2 ± 15.3 years in the warfarin group, with males comprising 75% and 72%, respectively. All-cause mortality (14% vs. 16%; HR 0.88, p = 0.65) and stroke (14% vs. 17%; HR 0.83, p = 0.50) did not differ significantly. Gastrointestinal bleeding was significantly lower with apixaban (12% vs. 25%; HR 0.51, p = 0.01). These observational analyses support apixaban as a feasible alternative anticoagulation strategy in HM3 LVAD recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.